181 related articles for article (PubMed ID: 34778047)
1. Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US.
Chen J; Han M; Liu A; Shi B
Front Oncol; 2021; 11():734594. PubMed ID: 34778047
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis.
Wu Y; Hu S; Liu X; Chen Y; Luan J; Wang S
Cost Eff Resour Alloc; 2024 Apr; 22(1):32. PubMed ID: 38659013
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China.
Wang L; Liu L; Zhang Z; Li F; Ruan Y; He Y; Huang J; Zheng X
Clin Breast Cancer; 2024 Apr; ():. PubMed ID: 38760263
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.
Lang Y; Chai Q; Tao W; Liao Y; Liu X; Wu B
Breast; 2023 Apr; 68():173-180. PubMed ID: 36780838
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.
Xie J; Li S; Li Y; Li J
BMC Health Serv Res; 2023 Jun; 23(1):706. PubMed ID: 37386633
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Shi D; Li Y; Liang X; Chen L
Front Oncol; 2023; 13():1162360. PubMed ID: 37251935
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.
Cher BP; Goh S; Aziz MIA; Wong G; Ng Chee Hui R; Ong BS; Ng KH
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):217-225. PubMed ID: 38149409
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Rui M; Shi F; Shang Y; Meng R; Li H
Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Shi B; Ma W; Pan H; Shi Y; Zhang H; Xing S
Front Pharmacol; 2022; 13():860615. PubMed ID: 35847009
[No Abstract] [Full Text] [Related]
10. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Shi Y; Chen J; Shi B; Liu A
Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
[TBL] [Abstract][Full Text] [Related]
13. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
14. Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
Kalinsky K; Spring L; Yam C; Bhave MA; Ntalla I; Lai C; Sjekloca N; Stwalley B; Stokes M; Taylor A; Nanda R
Breast Cancer Res Treat; 2024 Jun; ():. PubMed ID: 38904892
[TBL] [Abstract][Full Text] [Related]
15. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Bardia A; Tolaney SM; Punie K; Loirat D; Oliveira M; Kalinsky K; Zelnak A; Aftimos P; Dalenc F; Sardesai S; Hamilton E; Sharma P; Recalde S; Gil EC; Traina T; O'Shaughnessy J; Cortes J; Tsai M; Vahdat L; Diéras V; Carey LA; Rugo HS; Goldenberg DM; Hong Q; Olivo M; Itri LM; Hurvitz SA
Ann Oncol; 2021 Sep; 32(9):1148-1156. PubMed ID: 34116144
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
Loibl S; Loirat D; Tolaney SM; Punie K; Oliveira M; Rugo HS; Bardia A; Hurvitz SA; Brufsky AM; Kalinsky K; Cortés J; O'Shaughnessy JA; Dieras V; Carey LA; Gianni L; Gharaibeh M; Preger L; Phan S; Chang L; Shi L; Piccart MJ
Eur J Cancer; 2023 Jan; 178():23-33. PubMed ID: 36379186
[TBL] [Abstract][Full Text] [Related]
17. First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
Weng X; Huang X; Li H; Lin S; Rao X; Guo X; Huang P
Am J Clin Oncol; 2020 May; 43(5):340-348. PubMed ID: 32028340
[TBL] [Abstract][Full Text] [Related]
18. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
[TBL] [Abstract][Full Text] [Related]
20. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]